Tango Therapeutics (TNGX) Enterprise Value (2020 - 2026)

Tango Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$379.8 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 75.26% year-over-year to -$379.8 million; the TTM figure through Mar 2026 stood at -$379.8 million (down 75.26% YoY), while the FY2025 annual figure was -$112.7 million, up 56.73% from the prior year.
• Enterprise Value was -$379.8 million for Q1 2026 at Tango Therapeutics, down from -$112.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$59.4 million in Q3 2023 to a low of -$449.9 million in Q1 2022.
• Historically, Enterprise Value has averaged -$206.2 million across 5 years, with a median of -$180.8 million in 2025.
• Biggest YoY gain for Enterprise Value was 79.98% in 2022; the steepest drop was 583.81% in 2022.
• A 5-year view of Enterprise Value shows it stood at -$60.5 million in 2022, then retreated by 11.15% to -$67.3 million in 2023, then plunged by 287.14% to -$260.5 million in 2024, then surged by 56.73% to -$112.7 million in 2025, then tumbled by 237.01% to -$379.8 million in 2026.
• The last three Enterprise Value figures came in at -$379.8 million (Q1 2026), -$112.7 million (Q4 2025), and -$152.8 million (Q3 2025), per Business Quant data.